Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
6,235,531
-
Number of holders
-
86
-
Total 13F shares, excl. options
-
11,233,767
-
Shares change
-
-539,110
-
Total reported value, excl. options
-
$148,303,713
-
Value change
-
-$10,358,565
-
Put/Call ratio
-
86%
-
Number of buys
-
44
-
Number of sells
-
-39
-
Price
-
$13.2
Significant Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) as of Q2 2022
110 filings reported holding BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2022.
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) has 86 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 11,233,767 shares
.
Largest 10 shareholders include FMR LLC (4,197,356 shares), Artemis Investment Management LLP (1,384,938 shares), VANGUARD GROUP INC (995,538 shares), MASSACHUSETTS FINANCIAL SERVICES CO /MA/ (423,021 shares), Rubric Capital Management LP (391,650 shares), STATE STREET CORP (365,256 shares), GEODE CAPITAL MANAGEMENT, LLC (343,698 shares), MORGAN STANLEY (226,835 shares), NORTHERN TRUST CORP (205,983 shares), and MILLENNIUM MANAGEMENT LLC (188,548 shares).
This table shows the top 86 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.